Loading clinical trials...
Loading clinical trials...
Patients with end-stage kidney disease (ESKD) have an increased risk of cardiovascular mortality. High parathyroid hormone (PTH) from secondary hyperparathyroidism leads to increased efflux of phospha...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Iain Bressendorff
NCT03633708 · Secondary Hyperparathyroidism, Chronic Kidney Disease
NCT06660277 · Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD), and more
NCT06700876 · Tuberculosis (TB), End-Stage Kidney Disease
NCT04922892 · Secondary Hyperparathyroidism;Parathyroidectomy
NCT06842927 · End-Stage Kidney Disease, End Stage Renal Disease (ESRD), and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions